Octagon Capital Advisors LP Portfolio Holdings

Octagon Capital Advisors LP

  • $449 Million
  • Q4 2024

Octagon Capital Advisors LP has filed its 13F form on February 14, 2025 for Q4 2024 where it was disclosed a total value porftolio of $449 Million distributed in 33 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Apellis Pharmaceuticals, Inc. with a value of $96M, Centessa Pharmaceuticals PLC with a value of $33.4M, Verona Pharma PLC with a value of $26.5M, Nuvation Bio Inc. with a value of $24.5M, and Insmed Inc with a value of $22.9M.

Examining the 13F form we can see an increase of $34.5M in the current position value, from $414M to 449M.

Octagon Capital Advisors LP is based out at New York, NY

Below you can find more details about Octagon Capital Advisors LP portfolio as well as his latest detailed transactions.

Portfolio value $449 Million
Healthcare: $449 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$2.64B
$96 Million 21.39% of portfolio
3,006,980
Q3 2024 Added 4.38%
$1.42B
$33.4 Million 7.44% of portfolio
1,993,052
Q4 2024 Reduced 0.94%
$4.02B
$26.5 Million 5.91% of portfolio
571,264
Q4 2024 Reduced 68.87%
$395M
$24.5 Million 5.46% of portfolio
9,202,907
Q4 2024 Reduced 24.39%
$10.3B
$22.9 Million 5.11% of portfolio
332,000
Q4 2024 Reduced 24.0%
$460M
$21.6 Million 4.81% of portfolio
2,763,000
Q4 2024 Added 111.72%
$1.87B
$21.1 Million 4.7% of portfolio
488,000
Q4 2024 New
$456M
$20.7 Million 4.62% of portfolio
2,425,000
Q1 2024 New
$78.3M
$18.1 Million 4.03% of portfolio
10,450,000
Q4 2024 Added 128.55%
$575M
$16.7 Million 3.72% of portfolio
870,000
Q3 2024 Added 40.32%
$111M
$16.5 Million 3.68% of portfolio
18,350,000
Q4 2024 Added 99.72%
$638M
$15.7 Million 3.51% of portfolio
668,000
Q4 2024 Added 154.26%
$517M
$14.9 Million 3.33% of portfolio
778,000
Q4 2024 Added 25.39%
$2.09B
$13 Million 2.89% of portfolio
308,000
Q4 2024 New
$156M
$12.9 Million 2.87% of portfolio
5,136,795
Q4 2024 New
$4.89B
$12.1 Million 2.7% of portfolio
441,600
Q4 2024 Reduced 20.0%
$267M
$11.6 Million 2.59% of portfolio
1,370,000
Q4 2024 New
$8.28M
$7.9 Million 1.76% of portfolio
10,000,000
Q4 2024 Added 16.84%
$18.4M
$7.66 Million 1.71% of portfolio
4,848,802
Q4 2024 Added 13.72%
$53.2M
$1.67 Million 0.37% of portfolio
900,000
Q4 2024 New
$46.6M
$1.42 Million 0.32% of portfolio
992,000
Q2 2024 Reduced 0.8%
-
$0 0.0% of portfolio
-
Q3 2024 New
Arrivent Biopharma Inc
-
$0 0.0% of portfolio
-
Q4 2024 Added 4.2%
Corbus Pharmaceuticals Hldgs
-
$0 0.0% of portfolio
-
Q3 2024 Added 128.48%
Dianthus Therapeutics Inc
-
$0 0.0% of portfolio
-
Q4 2024 Added 20.81%
Helix Acquisition Corp Ii
-
$0 0.0% of portfolio
-
Q1 2024 New
Mind Medicine Mindmed Inc
-
$0 0.0% of portfolio
-
Q3 2024 Added 40.18%
Neurogene Inc
-
$0 0.0% of portfolio
-
Q4 2024 Added 1,920.0%
Perspective Therapeutics Inc
-
$0 0.0% of portfolio
-
Q4 2024 Added 62.05%
Allovir Inc
-
$0 0.0% of portfolio
-
Q4 2024 New

Summary

  • Portfolio
  • No. of Stocks 33
  • Current Value $449 Million
  • Prior Value $414 Million
  • Filing
  • Period Q4 2024
  • Filing Date February 14, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 7 stocks
  • Additional Purchases 11 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 5 stocks
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email